Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug;34(4):392-398.
doi: 10.1002/jca.21690. Epub 2019 Feb 13.

Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure

Jia Yao  1 , Shuang Li  2   3 , Li Zhou  2   3 , Lei Luo  4 , Lili Yuan  1 , Zhongping Duan  2   3 , Jun Xu  1 , Yu Chen  2   3
Affiliations

Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure

Jia Yao et al. J Clin Apher. 2019 Aug.

Abstract

Objective: The artificial liver support system (ALSS) is used frequently as a first-line treatment for hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF). This study aims to compare the therapeutic efficacy of double plasma molecular adsorption system (DPMAS) with sequential half-dose plasma exchange (PE) (DPMAS+PE) and full-dose PE in patients with HBV-ACLF.

Methods: A total of 131 hospitalized patients who were diagnosed with HBV-ACLF and underwent DPMAS+PE or PE were retrospectively analyzed. According to the treatment methods used, they were divided into PE group (n = 77) and DPMAS+PE group (n = 54). The main evaluation indexes included the change of liver function and the 28-days liver transplant-free survival rates after the different treatments.

Results: There were no significant differences on severity of illness between PE group and DPMAS+PE group (P > 0.05). The total bilirubin (TBIL) levels immediately after treatment, and at 24 and 72 hours after treatment were markedly decreased in DPMAS+PE group than that in PE group (52.3 ± 9.4% vs 42.3 ± 7.2%, P < 0.05; 24.2 ± 10.0% vs 13.5 ± 13.0%, P < 0.05; 24.8 ± 13.1% vs 14.9 ± 14.9%, P < 0.05; respectively). The 28-days survival rates was 62.3% and 72.2% in PE and DPMAS+PE groups (P = 0.146). Furthermore, the 28-days survival rates were significantly higher in DPMAS+PE group than that in PE group (57.4% vs 41.7%, P = 0.043) in the intermediate-advanced stage patients.

Conclusion: Compared with PE alone, DPMAS+PE might more effectively improve temporary TBIL in ACLF patients, and improve the 28-days survival rates in HBV-ACLF patients with intermediate-advanced stage. Therefore, DPMAS+PE may be an available ALSS treatment for HBV-ACLF patients.

Keywords: acute-on-chronic liver failure; artificial liver support; double plasma molecular absorption system; plasma exchange.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Changes in total bilirubin before and after treatment in the DPMAS+PE group and PE group
Figure 2
Figure 2
Comparison of the decline rates of total bilirubin (TBIL) at 24 and 72 hours after treatment between the DPMAS+PE group and PE group
Figure 3
Figure 3
Comparison of liver transplantation free hospital survival at 28‐days after treatment between PE group and DPMAS+PE group. (A)The included patients. (B) The early stage patients; (C) The intermediate‐advanced stage patients
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sarin SK, Kedarisetty CK, Abbas Z, et al. Acute‐on‐chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatol Int. 2014;8:453‐471. - PubMed
    1. Wu T, Li J, Shao L, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus‐related acute‐on‐chronic liver failure. Gut. 2017;67:2181‐2191. - PubMed
    1. Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology. 2014;60:2099‐2108. - PMC - PubMed
    1. Yuan D, Liu F, Wei YG, et al. Adult‐to‐adult living donor liver transplantation for acute liver failure in China. World J Gastroenterol. 2012;18:7234‐7241. - PMC - PubMed
    1. Shen Y, Wang XL, Wang B, et al. Survival benefits with artificial liver support system for acute‐on‐chronic liver failure: a time series‐based meta‐analysis. Medicine (Baltimore). 2016;95:e2506. - PMC - PubMed